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Clonal haematopoiesis harbouring AML-associated
mutations is ubiquitous in healthy adults
Andrew L. Young1,2, Grant A. Challen3, Brenda M. Birmann4 & Todd E. Druley1,2
Clonal haematopoiesis is thought to be a rare condition that increases in frequency with age
and predisposes individuals to haematological malignancy. Recent studies, utilizing
next-generation sequencing (NGS), observed haematopoietic clones in 10% of 70-year olds
and rarely in younger individuals. However, these studies could only detect common
haematopoietic clones—40.02 variant allele fraction (VAF)—due to the error rate of NGS.
To identify and characterize clonal mutations below this threshold, here we develop methods
for targeted error-corrected sequencing, which enable the accurate detection of clonal
mutations as rare as 0.0003 VAF. We apply these methods to study serially banked
peripheral blood samples from healthy 50–60-year-old participants in the Nurses’
Health Study. We observe clonal haematopoiesis, frequently harbouring mutations in
DNMT3A and TET2, in 95% of individuals studied. These clonal mutations are often stable
longitudinally and present in multiple haematopoietic compartments, suggesting a long-lived
haematopoietic stem and progenitor cell of origin.
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T
he advent of cost-effective, next-generation sequencing
(NGS) has permitted in-depth analysis of the spectrum
of somatic mutations driving clonal evolution in
malignancy1–3. Subsequently, benign clonal haematopoiesis
was identiﬁed in healthy individuals4–7. Recent studies
revealed that malignant and benign haematopoietic clones
frequently harbour mutations in the epigenetic modiﬁers
DNMT3A and TET2 (refs 1,8–11). Benign clones were rarely
detected before 60 years old, but were detected in 10–20% of
individuals older than 70 years old8–11. While compelling, these
previous studies could only detect common clonal mutations—
greater than 0.02 variant allele fraction (VAF)—due to the NGS
error rate. Haematopoietic clones detected above this 0.02 VAF
threshold have been termed clonal haematopoiesis of
indeterminate potential (CHIP) and are associated with an
increased risk of the developing haematological malignancy12.
Recently, the development of error-corrected sequencing (ECS)
using single molecule tagging with unique molecular identiﬁers
has permitted the detection of rare variants below the error rate
of NGS13–18. Here we combined ECS with targeted capture for
54 genes, recurrently mutated in acute myeloid leukaemia (AML)
to enable the detection of clonal mutations at VAFs two orders
of magnitude lower than the detection limit of NGS. Using
these methods, we sought to thoroughly describe the prevalence
and mutation proﬁle of rare haematopoietic clones in healthy
individuals, determine if these clones are stable longitudinally,
and determine if clonal mutations arise in long-lived
haematopoietic stem and progenitor cells (HSPCs) or in more
committed progenitors. We studied clonal haematopoiesis in
longitudinally banked blood samples from middle-aged healthy
participants in the Nurses’ Health Study (NHS). We found
clonal haematopoiesis, predominantly harbouring mutations in
DNMT3A and TET2, in 95% of individuals studied. Many
clonal mutations were stable longitudinally and detected in
both myeloid and lymphoid lineages, suggesting they arose in
long-lived HSPCs.
Results
Samples. We obtained paired buffy coat blood samples, banked
B10 years apart, from 20 healthy participants in the NHS
(Methods; Table 1)—a cohort of 121,701 female registered
nurses longitudinally studied since 1976 (refs 19–21). The median
ages at sample collection were 56.6 and 68.1 years old. This
facilitated the investigation of benign clonal haematopoiesis in
younger individuals, previously thought to only rarely harbour
haematopoietic clones8–12. To identify haematopoietic clones,
we combined ECS with targeted capture for 568 amplicons in
54 genes frequently mutated in AML (Methods)14–17.
This enabled us to sequence a tractable subset of the genome,
while still querying loci associated with clonal haematopoiesis and
AML. Samples were prepared and sequenced in duplicate. We
generated an average of 47.7 million paired-end sequencing reads,
which yielded an average of 3.4 million error-corrected consensus
sequences (ECCSs), per library (Supplementary Table 1).
Error-corrected NGS. We modelled position-speciﬁc errors in
the ECCSs using binomial statistics to identify clonal mutations
(Methods). We identiﬁed 109 clonal single nucleotide variants
(SNVs) in at least one time point o0.2 VAF in 95% (19/20)
of individuals. We detected 1–17, mostly exonic, SNVs per
individual at 0.0003–0.1451 (median 0.0024) VAF (Fig. 1a;
Supplementary Table 2). Of note, the median VAF we observed
was 10-fold less than the detection limit governing previous
studies of clonal haematopoiesis8–10. Separately, we identiﬁed
nine clonal insertion/deletion variants (indels) in six individuals
(Supplementary Table 3). Indels were identiﬁed by ECCS
coverage alone, as indel errors were not appropriately modelled
by the same statistical framework implemented to identify SNVs.
We were initially concerned that most of the identiﬁed rare
variants were artefacts introduced during library preparation or
sequencing. We ﬁrst determined that SNV calls were not biased
by coverage per amplicon (Supplementary Fig. 1) or by the
number of bases captured per gene (Supplementary Fig. 2).
Next, we validated these ﬁndings using droplet digital PCR
(ddPCR)—an orthogonal non-sequencing-based technique for
VAF quantiﬁcation. We designed ddPCR assays for 21 SNVs that
had been previously observed in malignancy22 and for one indel
(Methods; Supplementary Fig. 3). The VAFs measured by ECS
and ddPCR were highly correlated (R2¼ 0.98; Supplementary
Fig. 4; Supplementary Table 4), consistent with the previously
observed accuracy of ECS17.
We next compared the mutation proﬁle observed in these rare
haematopoietic clones to previous ﬁndings in CHIP and AML.
We detected 88 exonic clonal SNVs with 58 missense SNVs, 17
nonsense SNVs, 9 synonymous SNVs, 3 splicing SNVs and 1
SNV in a 30-UTR (Fig. 1b). While exonic variants were detected
in only 18 of the 54 genes in the panel, 64% (56/88) occurred in
the epigenetic regulators DNMT3A and TET2 (Fig. 1c). We
frequently detected multiple DNMT3A and TET2 mutations in
the same individual, which were not necessarily in the same clone
(Supplementary Fig. 5). The DNMT3A SNVs were predominantly
nonsense mutations in the 50 end of the gene or missense
mutations in the three functional domains (Supplementary
Fig. 6). For comparison, TET2 SNVs were primarily missense
mutations in the functional domains or nonsense mutations
throughout the gene (Supplementary Fig. 7), consistent with
previous observations of AML23. While less prevalent, intronic
clonal SNVs were observed in 12 genes with 29% (6/21) detected
in DNMT3A and 5% (1/21) detected in TET2 (Supplementary
Figs 8,9). The most common type of exonic substitution was the
cytosine to thymine (C to T) transition (Fig. 1d), as previously
observed in CHIP8–10. Conversely, intronic SNVs were evenly
distributed across substitution types.
Longitudinal analyses. We characterized the temporal stability of
these clones by tracking clonal mutations longitudinally within
Table 1 | Age at sample collection for each NHS participant.
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our 20 study participants. Variants were called independently
from paired samples bankedB10 years apart (Fig. 2). Of the 109
clonal SNVs identiﬁed, 27.5% (30/109) were detected at both time
points, 13.8% (15/109) were detected at only the ﬁrst time point
and 58.7% (64/109) were detected at only the second time point
(Supplementary Table 2). The stability of VAFs observed here
was consistent with the previous observations at higher VAFs in a
few instances of CHIP8. The presence of the same clonal
mutations longitudinally suggested that these mutations arose in
long-lived HSPCs or committed progenitors.
To further elucidate the cell of origin for clonal haematopoiesis,
we sorted 26 samples from 13 individuals into B lymphocyte
(CD45þCD33–CD19þ ), T lymphocyte (CD45þCD33–CD3þ )
and myeloid (CD45þCD33þ ) compartments using ﬂow
cytometry (Methods; Supplementary Fig. 10). While cell recovery
was variable per sample, we observed the same clonal SNVs in both
myeloid and lymphoid compartments in 10/13 individuals (Fig. 3;
Supplementary Table 5). Frequently, the VAF measured in the bulk
sample was approximately equal to the VAF measured in each
compartment. These observations were unlikely to have arisen due
to contamination, given that variants were often detected at similar
VAFs in different sorted compartments.
Discussion
These ﬁndings suggest that clonal haematopoiesis-harbouring
mutations in AML-associated genes is nearly ubiquitous (95%) in
50–70-year olds—an age group in which previous studies identiﬁed
haematopoietic clones in only 5% of individuals8–11. Clonal
mutations were detected in both the myeloid and lymphoid
compartments in samples banked a decade apart in these healthy
individuals, clearly demonstrating that these mutations arose in
long-lived HSPCs. However, these clonal mutations conferred only
a modest proliferation advantage, as most clonal mutations were
rare (median 0.0024 VAF) and stable longitudinally. One possible
explanation for these observations was that these mutations, often
in epigenetic regulators, augmented self-renewal capacity without a
concomitant increase in proliferation. This hypothesis may also
explain why HSPC number increases and quiescence decreases as a
function of age24,25. As HSPCs gradually senesce throughout life,
the acquisition of these mutations may allow benign clonal
haematopoiesis to maintain ostensibly normal blood production
years after it would otherwise decline26. This hypothesis is
supported by work in mice demonstrating that DNMT3A
loss-of-function mutations in haematopoietic stem cells (HSCs)




















































































































































Figure 1 | Number and characteristics of clonal SNVs detected by ECS in the peripheral blood of healthy adult nurses. (a) Clonal SNVs detected in each
individual, colour-coded by annotation. (b) Exonic clonal SNVs detected in each individual, colour-coded by predicted effect. (c) Detected exonic clonal
SNVs organized by gene, colour-coded by predicted effect. (d) Distribution of substitution types observed in clonal SNVs.
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increasing proliferation27. Comparably, TET2 loss-of-function
mutations in mice increase HSC self-renewal and proliferation28.
While DNMT3A mutations are frequently observed in CHIP
and AML1,8–11, we observed a different distribution of DNMT3A
mutations, speciﬁcally at the arginine 882 (R882) residue.
Previous studies showed that mutations in DNMT3A R882
comprised approximately two-thirds of total DNMT3A mutations
in AML29 and one-third of DNMT3A mutations in CHIP8,9.
However, we observed only a single DNMT3A R882H variant.
These ﬁndings suggest that DNMT3A R882 mutations potently
drive clonal expansion, explaining their prior detection
in common CHIP clones (median 0.11 VAF)8 and their rarity
in these lower frequency clones.
The detection limit of ECS wasB1:10,000 cells. Thus, given an
estimated 11,000 HSCs in adults, of which only a fraction actively
contribute to haematopoiesis at any given time30, we expected to
observe unique somatic mutations marking each active HSC
(a random distribution of synonymous and nonsynonymous
mutations throughout the 54 AML-associated genes captured).
Instead, over half of the detected mutations were in DNMT3A or
TET2. This observation alone could have occurred if DNMT3A
and TET2 were hotspots of somatic mutation. However, 89%
(78/88) of the detected exonic mutations were nonsynonymous,
truncating or splicing mutations. Given this skew towards
presumed functional mutations, it was more likely that these
haematopoietic clones were enriched by selection.
Due to technical limitations of our methods, we likely under-
reported the number of clonal mutations present in each
individual. Speciﬁcally, we likely underreported the number of C
to T (G to A) substitutions present in these rare haematopoietic
clones due to the stringency of the binomial variant calling strategy
and the background rate of cytosine deamination, which is a
predominant artefact of ECS14,16,31. Here 38/109 substitutions
identiﬁed were C to T (G to A) substitutions. Conversely, in
previous studies of CHIP and AML, C to T (G to A) substitutions
comprised B50–60% of identiﬁed substitutions8,9,32. In addition,
the binomial statistical framework underreported hotspot
mutations occurring in multiple individuals. However, in our
raw data we only observed a single likely instance of an uncalled






































































































Figure 2 | Longitudinal detection of clonal SNVs in NHS participants. Clonal SNVs were detected by ECS in both time points for 16/20 NHS participants.
For each participant ID (PID), the VAF measured by ECS was plotted relative to the age at sample collection. Variants detected in both time points were
connected with a line.
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observed at a lower VAF than the variant reported in individual 13.
In addition, we could not routinely co-localize mutations within
the same haematopoietic clone. However, we co-localized
mutations in three instances where they co-occurred in the same
sequenced reads (participant ID (PID) 2, TET2 R1216G/A1217A;
PID 13, DNMT3A G498V/C494F; PID 14, KRAS A66A/S65S).
Future adaptations of this technology could address these
limitations by targeting a larger capture panel and implementing
single-cell sequencing approaches.
In summary, we demonstrate that clonal haematopoiesis,
originating in long-lived HSPCs, is far more common than
previously thought in healthy middle-aged adults. Despite its
prevalence, clonal haematopoiesis shares many mutations with
AML, raising additional questions regarding the sequence of
mutation acquisition and cooperating events necessary for
malignant transformation. Furthermore, in previous studies of
CHIP the detection of a haematopoietic clone (at any age) was
associated with an 11–13-fold increased risk of developing a
haematological malignancy8,9. These earlier ﬁndings suggested that
CHIP was comparable to monoclonal gammopathy of
undetermined signiﬁcance and monoclonal B-cell lymphocytosis,
which are benign clonal proliferative conditions that occasionally
progress to haematological malignancy6,7,12. Conversely, our
ﬁndings suggest that clinically silent clonal haematopoiesis is
present in almost all individuals by middle age, and that progression
to haematological malignancy is exceptionally rare. Given the
current public interest in precision medicine33, these ﬁndings have
practical implications for sequencing-based screening of nascent
malignancy or recurrence. Future research must focus on reliably
distinguishing benign clonal haematopoiesis, however rare, from
malignant clonal haematopoiesis that could drive transformation
and relapse. This imperative extends to sequencing-based non-
invasive screening34, which will require even ﬁner discrimination
between nascent malignancy and benign clonal expansion.
Methods
Study population. The NHS began in 1976 with 121,701 female United States
registered nurses age 30–55 years old who returned an enrolment questionnaire,
which queried medical history, anthropometric measures and lifestyle/environmental
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Figure 3 | Haematopoietic compartment-speciﬁc detection of clonal SNVs in NHS participants. Paired buffy coat samples from 13 individuals were
sorted into B lymphocyte (pink), T lymphocyte (purple) and myeloid (blue) compartments using ﬂow cytometry. For each NHS participant ID (PID), a
single SNV, detected by ECS, was selected for compartment-speciﬁc quantiﬁcation by ddPCR. Variants detected in both time points were connected with a
line. The VAF measured by ddPCR in the bulk sample (green) was included for comparison.
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questionnaires to update information on potential exposures and diagnoses of
chronic disease. To date, follow-up rates have been consistently high (490%). In
1989–1990, 32,826 women provided a heparinized whole blood sample by methods
described previously20. In 2000–2001, 18,743 of the women who had provided a
sample in 1989–1990 provided a second whole blood sample using the same
protocol21. In brief, participants willing to provide blood samples received kits that
included all supplies necessary for their collection and overnight return (including a
chill pack), and a brief questionnaire. Upon receipt, specimens were separated into
plasma, buffy coat and red blood cell fractions, and frozen in liquid nitrogen.
Informed consent to participate in the NHS was implied by return of the enrolment
and follow-up questionnaires; written informed consent was obtained for biomarker
studies at time of blood collection.
Among women who provided blood samples in 1989–1990 and 2000–2001, we
identiﬁed 20 with no history of cancer or other major chronic disease. De-identiﬁed
aliquots from those 40 buffy coat samples were prepared and shipped overnight to
Washington University for the detection of persistent rare haematopoietic clones
harbouring AML-associated somatic mutations as described below. Since each
sample was de-identiﬁed and the capture space for targeted genomic DNA
sequencing was not enough to enable the individual identiﬁcation (141 kb per
person), the Washington University Human Research Protection Ofﬁce deemed
this study as non-human research.
Sample preparation for ECS. Genomic DNA was extracted from 50 ml of puriﬁed
buffy coat from each sample using the QIAmp DNeasy Blood and Tissue Kit
(Qiagen) with MinElute columns (Qiagen) instead of standard columns to facilitate
elution in a lower volume (three 30 ml elutions). The concentration of the
extracted genomic DNA was measured using the Qubit dsDNA HS Assay Kit
(Life Technologies). Enrichment of 568 amplicons in 54 genes (141 kb) commonly
mutated in AML was performed using 250 ng of genomic DNA via the Illumina
TruSight Myeloid Panel (Illumina). Technical replicates were prepared for each
sample (80 libraries total). Following extension–ligation, the ampliﬁed fragments
were eluted in 50mM NaOH. Recovered fragments were ampliﬁed using the Q5
High-Fidelity 2x Master Mix (New England Biolabs) in a 75 ml reaction
(37.5 ml 2x master mix, 20 ml DNA in 50mM NaOH, 2ml Tris-HCl pH 7.5 and
0.4 mM i5/i7 primers). Illumina’s standard i7 primers were used to enable sample
multiplexing. The i5 primer was redesigned to contain a random 16 nucleotide
index to facilitate ECS (Supplementary Table 6). The following conditions were
used for ampliﬁcation: 98C for 30 s; six cycles of 98 C for 10 s, 66 C for 30 s, 72 C
for 30 s; 72 C for 2min; hold 10 C. The PCR reaction was puriﬁed using a
modiﬁed Ampure bead (Beckman Coulter) clean up to purify the ampliﬁed
fragments (4400 bp). A modiﬁed poly-ethylene glycol (PEG) solution was made
containing 382.5 ml 50% wt/vol PEG (Sigma), and 562.5 ml 5M NaCl and 555 ml
ddH2O. One-hundred microlitres of beads were washed twice with ddH2O to
remove the stock PEG solution. One-hundred-ﬁfty microlitres of the modiﬁed PEG
solution was added to the washed Ampure beads with the 75 ml PCR reaction and
otherwise puriﬁed using the standard Ampure protocol. The fragments were eluted
in 20ml ddH2O and the concentration of each library was quantiﬁed with Qubit
(Life Technologies).
Quantiﬁcation by ddPCR. Our goal was to generate each ECS library from 4M
uniquely tagged molecules. We quantiﬁed each library’s concentration using the
QX200 ddPCR platform (Bio-Rad). A 2 ml aliquot of each library was diluted 1,000-
fold and quantiﬁed in duplicate wells. Each well contained the following reaction
mixture: 10ml 2 EvaGreen 2 ddPCR master mix (Bio-Rad), 5 ml 1:1,000
diluted ECS library, 100 nM P5/P7 primers (Supplementary Table 6) and ddH2O
added to 20 ml total. Droplets were generated using the standard Bio-Rad protocol.
Ampliﬁcation was completed using the following conditions: 95 C for 5min; 40
cycles of 95 C for 30 s, 66 C for 1min; 4 C for 5min; 90 C for 5min; 4 C hold.
With the calculated concentration, we aliquotted the appropriate volume of each
library to introduce 4M molecules into the subsequent ampliﬁcation step.
Ampliﬁcation and normalization. Following ddPCR quantiﬁcation, 4M molecules
for each library were ampliﬁed using Q5 High-Fidelity 2 Master Mix
(New England Biolabs) using 1 mM P5/P7 primers (Supplementary Table 6) in a
50ml reaction under the following conditions: 98 C for 30 s; 16 cycles of 98 C for
10 s, 66 C for 30 s, 72 C for 30 s; 72 C for 2min; 4 C hold. The PCR reaction was
puriﬁed using the modiﬁed Ampure bead clean up. One-hundred microlitres of
beads were washed twice with ddH2O and replaced with 100 ml of the modiﬁed
PEG solution described above. The PCR reaction was then added to the mixture
and puriﬁed using the standard protocol. The fragments were eluted in 20 ml
ddH2O. A 2 ml aliquot of each library was diluted 10-fold and quantiﬁed on the
Agilent 2200 Tape Station. Libraries were then pooled in equimolar groups of eight.
Once pooled, each library was again quantiﬁed on the Tape Station and submitted
for sequencing.
Sequencing. Each library was sequenced on the Illumina NextSeq platform
using a 300 cycle high output kit as speciﬁed by the manufacturer. Approximately
5–10% of PhiX control DNA was spiked into each sequencing experiment.
Each sequencing run contained roughly 400M paired-end 144 bp reads with
corresponding 16 bp unique molecular index and 8 bp sample-speciﬁc index
sequences. Sequenced reads were demultiplexed by sample-speciﬁc index allowing
for at most one mismatch in the index sequence (Supplementary Table 1).
Raw sequence reads were aligned to the PhiX genome using Bowtie 2 (ref. 35).
Sequence reads that did not align to PhiX were retained for the subsequent
analysis (below).
ECS analysis. The ﬁrst 30 nucleotides of each sequenced read were hard clipped to
remove the primer sequences from the TruSight Myeloid panel. Next, the sequenced
read pairs tagged with the same random index sequence (originating from the same
uniquely tagged DNA molecule) were aligned to each other to generate read families
in a manner similar to the previously published methods14–17. Read families were
required to have ﬁve or more reads sharing the same index sequence. Paired-end
reads within a read family were error corrected to generate an ECCS in a stepwise
manner. First, at every position, the nucleotides called by each sequence read were
compared and a consensus nucleotide was called if there was at least 90% agreement
between the reads. If there waso90% agreement, an N was called in the consensus
sequence at that position. Errors that occurred during the library preparation and
sequencing were corrected or removed because they were not shared between
different reads within a read family. Second, an ECCS was discarded if410% of the
228 nucleotides comprising the paired-end read were reported as N nucleotides.
ECCSs were then locally aligned to UCSC hg19/GRCh37 using Bowtie2 and
realigned with GATK’s Indel Realigner36. Next, the aligned ECCSs were processed
with Mpileup using the parameters -BQ0 -d 10,000,000,000,000. This removed the
coverage thresholds to ensure that all of the pile up output was returned regardless of
VAF or coverage. The parsed pile up output was further ﬁltered to ignore positions
with o1,000x ECCS coverage or outside of the Illumina TruSight Myeloid target
space. In addition, germline variants identiﬁed by the 1,000 Genomes Project above a
0.01 minor allele fraction were excluded from the analysis.
We implemented a position-speciﬁc binomial error model to improve rare
clonal SNVs calling as described previously17. For each sample, we generated a
nucleotide position-speciﬁc error proﬁle using all sequenced libraries that were not
from the same individual. A variant was called if: (a) the binomial P value was
o0.05 after Bonferroni correction; (b) the variant was observed in at least ﬁve
ECCSs; (c) the VAF was 40.0001; and (d) the variant was identiﬁed with
criteria a–c in at least two replicates from one of the two time points. Likely,
clonal SNVs (o0.2 VAF) were reported and annotated using Annovar37, with the
COSMIC 68 (ref. 22) and 1,000 Genomes (October 2014 release)38 databases.
The amino-acid substitutions were predicted based on the canonical transcript
reported in the GENCODE (v22)39 as retrieved from the UCSC Table Browser40.
We identiﬁed potential insertion/deletion (indel) events using VarScan 2
(ref. 41), from the ﬁltered Mpileup output (described above), with the following
parameters: min-coverage 1,000; min-reads2 5; min-var-freq 0.001; strand-ﬁlter 0;
and output-vcf 1. We ﬁltered out single-nucleotide indels in homopolymer runs at
least four nucleotides long and indels that were observed in multiple samples to
remove technical artefacts in the variant calling. We reported likely clonal indels
(o0.2 VAF) that were detected in at least two replicates from one of the collection
time points. Reported indels were annotated with Annovar37 as described
previously.
ddPCR validation. We validated 21 SNVs and 1 indel using the ddPCR probe
assay (Bio-Rad)42. Probes were designed by Bio-Rad based on MIQE guidelines for
the quantitative digital PCR43. All reagents were purchased from Bio-Rad.
For each sample and control, 45 ng of the genomic DNA was aliquoted per well of
generated droplets. We generated between 8 and 32 wells of droplets for each
validation experiment, depending on the expected VAF for the assayed mutation.
Each control sample was assayed with the same number of wells as the
corresponding sample. Droplets were generated on the QX200 Droplet
Generator (Bio-Rad) and assayed on the QX200 droplet reader (Bio-Rad) using the
standard protocol42. The VAF was estimated from droplets lacking the reference
allele and the Poisson-estimated number of singleton droplets as described
previously17.
Flow cytometry. Cells were sorted from the buffy coat samples using a Sony iCyt
Synergy SY3200 BSC 17-colour, 5-laser cell sorter (Sony Biotechnology Inc.) and
analysed with FlowJo (Treestar) using standard protocols (Supplementary Fig. 10).
Cells were stained with the following antibodies (BioLegend): CD45 (BV-421),
CD33 (APC), CD19 (FITC) and CD3 (PE-CY7) per the manufacturer’s
instructions. Variants were detected in puriﬁed cell populations using the ddPCR
assay described previously.
Data availability. The sequencing data have been deposited into the NCBI
Sequence Read Archive under accession number SRP078948. All other relevant
data are included in the article or supplementary ﬁles, or available from the authors
upon request.
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